Guardian Partners Inc. Purchases New Shares in Pfizer Inc. (NYSE:PFE)

Guardian Partners Inc. purchased a new stake in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 128,651 shares of the biopharmaceutical company’s stock, valued at approximately $3,456,000.

A number of other institutional investors have also made changes to their positions in the business. Retirement Wealth Solutions LLC bought a new stake in Pfizer during the 4th quarter worth about $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer during the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the 4th quarter worth about $28,000. Noble Wealth Management PBC bought a new stake in Pfizer during the 4th quarter worth about $31,000. Finally, Curio Wealth LLC bought a new stake in Pfizer during the 4th quarter worth about $32,000. 68.36% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $26.20 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50 day simple moving average of $26.17 and a 200 day simple moving average of $27.04. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The firm has a market capitalization of $148.61 billion, a PE ratio of 18.58, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the firm earned $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on PFE. Citigroup dropped their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.